How valuable are your customers in the brand value co-creation process? The development of a Customer Co-Creation Value (CCCV) scale.

Despite an increasing amount of research on co-creation of value, in general, research on brand value co-creation remains limited. Particularly, how much value customers contribute to the brand value co-creation process remains unclear. This research develops in a series of eight studies the Customer Co-Creation Value (CCCV) measurement scale that helps firms assess the value of customers in the brand value co-creation process. The findings reveal that CCCV is a multidimensional construct consisting of two higher-order factors and seven dimensions: customer-owned resources (including brand knowledge, brand skills, brand creativity, and brand connectedness) and customer motivation (comprising brand passion, brand trust, and brand commitment). Further, the CCCV scale reliably and validly gauges the value customers contribute to a firm's brand. The CCCV framework helps marketing managers understand how customers can contribute to a firm's brand value cocreation efforts and how much value customers contribute to a brand in the co-creation process

Additional file 1: of Oral fosfomycin for treatment of urinary tract infection: a retrospective cohort study

Spreadsheet reporting 75 unique patients treated with fosfomycin for urinary tract infections. This excel file contains anonymised details of 75 unique adult patients treated with fosfomycin for urinary tract infections at Oxford University Hospitals NHS Foundation Trust from March 2013 through June 2015. Our original analysis also included patient sex, but this has been removed from the suppl. data file in order to protect anonymity. (XLSX 24 kb

Additional file 2: of Oral fosfomycin for treatment of urinary tract infection: a retrospective cohort study

Tabulated summary of studies that have informed current NICE guidelines for fosfomycin use in UTI. This table contains a brief summary of four studies from Europe/North America that are referenced by current NICE guidelines regarding the use of oral fosfomycin for treatment of UTI, including date of study, cohort location, study design and cure data. (DOCX 88 kb

Parvocellular expression of AVPmRNA, CRHmRNA and iNOS in control and septic shock patients and in sham, septic and septic ED rats.

<p>Abbreviations: AVP, Vasopressin; CRH, Corticotropin Releasing Hormone; mRNA, messenger RNA; iNOS, inducible nitric oxide synthase; ED, Early death.</p><p>Results are expressed as median (IQR).The index of labelling CRH and AVP <i>in-situ</i> hybridization and iNOS immunohistochemistry ranged from 0 to 3.</p><p>Comparison between the following animal groups:</p>a<p>Sham <i>versus</i> Sepsis,</p>b<p>Sepsis <i>versus</i> Septic Shock,</p>c<p>Sham <i>versus</i> Septic Shock.</p

Antehypophyseal expression of ACTH, CRHR1 and V1b receptor in control and septic shock patients and in sham, septic and septic ED rats.

<p>Abbreviations: ACTH, Adreno-Corticotropic Hormone; V1b, Vasopressin receptor 1b; CRHR1, Corticotropin Releasing Hormone receptor 1; ED, Early death.</p><p>Results are expressed as median (IQR). The index of labelling of ACTH, CRHR1 and V1b receptor immunohistochemistry ranged from 0 to 3.</p><p>Comparison between the following animal groups:</p>a<p>Sham <i>versus</i> Sepsis,</p>b<p>Sepsis <i>versus</i> Septic Shock,</p>c<p>Sham <i>versus</i> Septic Shock.</p

PVN of patients who died from non-septic causes (A–C–E) or septic shock (B–D–F).

<p>CRH mRNA (A–B) and AVP mRNA (C–D) labelling after <i>in situ</i> hybridization expression did not differ between the two groups. iNOS (E–F) expression after immunohistochemistry (ABC peroxidase/DAB) was higher in septic shock patients.</p

Ante-hypophysis of patients who died from non-septic causes (A–C–E) or septic shock (B–D–F).

<p>Labelling of CRHR1 (A–B) and V1b receptor (C–D) after immunohistochemistry (ABC peroxidase/DAB) did not vary among the two groups. ACTH (E–F) immunostaining (ABC peroxidase/DAB) was decreased in septic shock patients.</p

Antibodies.

<p>*H: human; R: rat.</p